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Abstract
: Malaria during pregnancy is a major health risk for both theBackground
mother and the foetus. Pregnancy has been shown to influence the
pharmacokinetics of a number of different antimalarial drugs. This might lead to
an under-exposure in these patients which could increase the risk of treatment
failure and the development of drug resistance. The study aim was to evaluate
the pharmacokinetics of artesunate and dihydroartemisinin in pregnant and
non-pregnant patients using a population modelling approach.
: Twenty-four women in their second and third trimester of pregnancyMethods
and twenty-four paired non-pregnant women, all with uncomplicated P.
 malaria, were enrolled in this study. Treatment was a fixed-dosefalciparum
combination of oral artesunate and mefloquine once daily for three days.
Frequent blood samples were collected and concentration-time data for
artesunate and dihydroartemisinin were analysed simultaneously using
nonlinear mixed-effects modelling.
: Artesunate pharmacokinetics was best described by aResults
transit-compartment absorption model followed by a one-compartment
disposition model under the assumption of complete   conversion ofin vivo
artesunate into dihydroartemisinin. Dihydroartemisinin pharmacokinetics was
best described by a one-compartment disposition model with first-order
elimination. Pregnant women had a 21% higher elimination clearance of
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 elimination. Pregnant women had a 21% higher elimination clearance of
dihydroartemisinin, compared to non-pregnant women, resulting in
proportionally lower drug exposure. In addition, initial parasitaemia and liver
status (alanine aminotransferase) were found to affect the relative
bioavailability of artesunate.
: Results presented here show a substantially lower drugConclusions
exposure to the antimalarial drug dihydroartemisinin during pregnancy after
standard oral treatment of artesunate and mefloquine. This might result in an
increased risk of treatment failure and drug resistance development, especially
in low transmission settings where relative immunity is lower.
: ClinicalTrials.gov   (19/06/2008)Trial registration NCT00701961
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Introduction
Malaria infection during pregnancy has been associated with 
major adverse health outcomes for both the mother and the 
foetus. In 2007, there were an estimated 85 million preg-
nancies in areas of endemic P. falciparum malaria1. Preg-
nant women are more likely to get bitten by the vector, and 
to develop severe malaria2,3. Malaria during pregnancy has 
also adverse consequences for the foetus resulting in an increased 
risk of intrauterine growth retardation, low birth weight, still-
birth, and infant morbidity and mortality4. The World Health 
Organization (WHO) is today recommending artemisinin based 
combination therapy (ACT) as first line therapy of uncomplicated 
P. falciparum malaria. This recommendation includes pregnant 
women in their second and third trimester5,6. ACTs include an 
artemisinin derivative (i.e. artesunate, artemether, dihydroar-
temisinin) together with a longer acting drug (i.e. mefloquine, 
piperaquine, lumefantrine, amodiaquine)7. The artemisinins are 
highly effective, resulting in rapid parasite clearance during the 
first days of treatment8. The longer acting partner drugs are respon-
sible for eliminating residual parasites to prevent recrudescent 
malaria.
Artesunate is rapidly converted by pre-systemic hydrolysis, 
systemic esterases and cytochrome P450 (CYP) 2A6 into its 
active metabolite dihydroartemisinin9,10. Dihydroartemisinin 
is metabolized into inactive metabolites by glucuronidation by 
UDP-glucuronosyltransferase (UGT) 1A9 and 2B711.
Pregnancy-related changes in the exposure to artesunate and dihy-
droartemisinin have been studied previously12–14. Morris et al. 
found a pregnancy-related increase in dihydroartemisinin clear-
ance after oral artesunate treatment, resulting in approximately 
42% lower drug exposure. Kloprogge et al. studied both intrave-
nous and oral doses of artesunate in pregnant and non-pregnant 
women. Intravenous administration of artesunate showed similar 
disposition pharmacokinetics in both pregnant and non-pregnant 
women. However, a 23% decreased bioavailability of artesu-
nate was observed after oral dosing which was explained by 
an increased pre-systemic activity during pregnancy.
A few other antimalarial drugs (e.g. chloroquine, lumefantrine and 
dihydroartemisinin) have shown a lower drug exposure in pregnant 
women compared to non-pregnant women, resulting in an increased 
risk for treatment failure and resistance development15–21.
The main aim of the present study was to evaluate the popula-
tion pharmacokinetics of artesunate and its active metabolite, 
dihydroartemisinin, in a comparative study in pregnant and 
non-pregnant patients with  uncomplicated P. falciparum malaria 
in Burkina Faso.
Methods
Study design and ethical approval
The study was conducted at the Nanoro District Hospital, Nanoro 
in Burkina Faso from 7 September 2008 to 15 January 2009. 
Clinical details and results from a non-compartmental analysis 
has been published previously22. The investigation was a non- 
randomised parallel open label trial in pregnant and non-pregnant 
women with uncomplicated P. falciparum mono-infection. The 
study was approved by the National Health Ethics Committee in 
Burkina Faso (014-2008/CE-CM). The study was registered at 
www.clinicaltrials.gov (NCT00701961) on June 19th 2008.
Study subjects
Pregnant and non-pregnant women with uncomplicated 
P. falciparum malaria mono-infection (defined as <50 000 
parasites/µL and with no danger signs of severe malaria) were 
identified in two health facilities, the Centre de Sante´ et de 
Promotion Sociale (CSPS) of Nazoanga and of Nanoro, Burkina 
Faso. Non-pregnant women were selected to match the recruited 
pregnant women by age (either less or more than 20 years old) 
provided that they were residing in the same village as the preg-
nant women. Inclusion criteria for the study were; gestational 
age of more than 12 weeks, P. falciparum infection with a para-
site density of less than 50,000 parasites/µL, willingness to sign 
or thumb print the written consent form, willingness to stay in 
the hospital for three days and to return for regular follow-up 
visits until delivery for treatment and observation, willingness 
to deliver at the health facility. A woman was excluded from 
the study if; she had a history of drug sensitivity to the studied 
drug or recent treatment with antimalarials or drugs known to 
interact with the studied drug, presence of any danger signs, 
physical findings of severe illness/severe anaemia, inability to 
tolerate oral medicine, chronic medical conditions requiring 
special care which could not be met by the study. Study proce-
dures and objectives were explained in the local language by the 
study physician before obtaining a signed informed consent.
Drug regimen and blood sampling
Treatment comprised a fixed-dose of artesunate/mefloquine- 
containing tablets (100 mg of artesunate and 220 mg of mefloquine) 
provided by Farmaguinhos, Rio de Janeiro, Brazil. A target 
daily dose of 8 mg/kg/day of mefloquine and 3.6 mg/kg/day 
of artesunate were given for three days to each patient. Number 
of tablets received was planned according to standard dosing 
according to body weight; women weighing <50 kg, 50–60 kg and 
>60 kg received a daily dose of 1.5, 2 and 2.5 tablets, respectively. 
Treatment was supervised and given after food.
Blood samples (2 mL) for pharmacokinetic analysis of artesu-
nate and dihydroartemisinin were obtained by venous puncture 
or via a three-way tap attached to a catheter. Samples were col-
lected before treatment and during the first day of treatment 
at time points: 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours 
after dose. All samples were placed on ice immediately after blood 
collection and processed within 15 minutes. Plasma samples 
were obtained after centrifugation at 1,500g for 10 minutes at 
4°C and stored in liquid nitrogen until shipment on dry ice to 
the Department of Clinical Pharmacology, MORU, Bangkok, 
Thailand, for measurement of drug concentrations.
Drug analysis
Samples were extracted by solid phase extraction and quantified 
using a validated liquid chromatography tandem mass spectrom-
etry (LC-MS/MS) method23. Briefly, artesunate and dihydroar-
temisinin standards and isotope-labelled internal standards were 
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provided by the WorldWide Antimalarial Resistance Network 
(WWARN). Separation was performed using an Agilent 1200 
system consisting of a binary LC pump, a vacuum degasser, a 
temperature-controlled micro wellplate autosampler set at 4°C and 
a column compartment set at 40°C (Agilent technologies, Santa 
Clara, USA). Quantification was performed using an API 5000 
triple quadrupole mass spectrometer (Applied Biosystems/MDS 
SCIEX, Foster City, USA), with a TurboVTM ionization source 
(TIS) interface operated in the positive ion mode.
Data acquisition was performed using Analyst 1.5 (Applied 
Biosystems/MDS Sciex, Foster City, CA, USA). The lower limit 
of quantification (LLOQ) was 1.2 ng/mL and 2.0 ng/mL for 
artesunate and dihydroartemisinin, respectively. The total assay 
coefficient of variation was less than 7% for all quality control 
samples of artesunate (i.e. 2.90, 51.7 and 546 ng/mL, <3.5%) and 
dihydroartemisinin (i.e. 5.87, 117 and 1880 ng/mL, <6.4%) in 
this study. The laboratory participates in the WorldWide Antima-
larial Resistance Network (WWARN) quality control and assur-
ance proficiency testing program with satisfactory performance24. 
Pharmacokinetic results of mefloquine will be reported 
elsewhere.
Pharmacokinetic analysis
The population pharmacokinetic properties of artesunate and 
dihydroartemisinin were analysed using nonlinear mixed-effects 
modelling of the logarithmic plasma concentrations (NONMEM 
version 7.1.2; ICON Development Solutions, MD). Pearl-Speaks- 
NONMEM (PsN; version 3.4.2), Pirana (version 2.4.0) and Xpose 
(version 4.0) package in R (version 2.13.1; The R Foundation 
for Statistical Computing) were used for post processing of the 
results and for automation of the modelling process25.
Artesunate and dihydroartemisinin were modelled simultane-
ously and complete conversion of artesunate into its metabolite, 
dihydroartemisinin, was assumed9,26. The first-order conditional 
estimation (FOCE) method with interactions was used in the 
model building process. Data below the LLOQ was modelled 
as missing data (M1), categorical data (M3) or fixed to half 
of the LLOQ (M5)27. When censored data were implemented 
with the M3-method a Laplacian estimation method was used.
Objective function value (OFV; proportional to minus twice the log 
likelihood of the observed data) and goodness-of-fit were used for 
model discrimination and graphical analysis, respectively. A drop 
in OFV of 3.84 was considered a significant (p=0.05) improve-
ment in model fit when comparing two hierarchical models 
(one degree of freedom difference). One- two- and three- 
compartment models with first-order elimination from the central 
compartment were fitted to the plasma concentration-time 
data. Several different absorption models were evaluated (zero-
order, first-order, absorption lag-time, sequential absorption, 
and a flexible transit compartment model with 1–10 fixed tran-
sit compartments). Inter-individual variability was evaluated 
exponentially on all parameters in the model (Eq. 1).
                           θ θ η= × exp( )i TV i                                     (Eq. 1)
where θi is the individual parameter for the ith patient and θTV is 
the typical value for parameter θ. ηi is the inter-individual vari-
ability for parameter θ, assumed to be normally distributed with 
mean zero and variance ω2. Relative bioavailability of artesunate 
was evaluated by fixing the population value to unity and estimating 
the inter-individual variability.
The residual random variability was modelled with two separate 
additive error models (i.e. artesunate and dihydroartemisinin) 
on the log-transformed drug concentrations, being essentially 
equivalent to an exponential residual error on an arithmetic 
scale.
Body weight was evaluated as an allometric function on all 
clearance and volume parameters. The allometrically scaled param-
eters were centered on the median body weight of the studied 
population and scaled to a power of 0.75 and 1 for clearance 
and volume parameters, respectively.
Stepwise forward inclusion (p<0.05) was used for all other 
continuous and categorical covariates followed by a stepwise 
backward exclusion (p<0.01). Parasite biomass, alanine ami-
notransferase (ALT), aspartate aminotransferase (AST), bilirubin 
levels, and haemoglobin levels at enrolment were tested as con-
tinuous covariates while pregnancy was evaluated as both a con-
tinuous (estimated gestational age; 0–8 months) and a categorical 
covariate (pregnant vs non-pregnant).
A categorical pregnancy effect was evaluated using a full 
covariate approach (i.e. the pregnancy effect was added simulta-
neously on relative oral bioavailability, all clearance parameters 
and on mean transit time). The full covariate model was boot-
strapped (n=500) and the 80% confidence interval of the covariate 
effect on each of the pharmacokinetic parameters visualized to 
investigate the clinical impact and the predicted variability of the 
covariate effect.
Basic graphical goodness-of-fit was evaluated by plotting 
observed artesunate and dihydroartemisinin concentrations against 
individually and population predicted concentrations and by 
plotting conditionally weighted residuals against population 
predicted concentrations and time. Eta and epsilon shrink-
ages were also evaluated to assess reliability of goodness-of-fit 
characteristics28. Prediction-correct visual predictive checks were 
performed using 2,000 simulations. Bootstrap diagnostics stratified 
on pregnancy, were performed using 1,000 re-sampled datasets to 
obtain standard errors for parameter estimates and non-parametric 
confidence intervals to evaluate parameter precision.
The final model was also used to simulate pregnant (n = 1,000) 
and non-pregnant (n = 1,000) women in order to investigate the 
differences in secondary exposure parameters (AUC and CMAX) 
associated with pregnancy. Simulated pregnant and non-pregnant 
women were identical with respect to body weight and other 
co-variates, except pregnancy. All individual exposure param-
eters were divided on the average value for a non-pregnant 
women, and presented as a box-plot to illustrate trends and 
variabilities.
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Results
48 pregnant (n = 24) and non-pregnant (n = 24) women com-
pleted the pharmacokinetic study (one pregnant woman was lost 
to follow-up due to moving out of the study area). No adverse 
effects, related to study treatment, were observed and treat-
ment efficacy was excellent in both groups with total parasite 
clearance by day three22. Consort checklist and flow-chart are 
available from figshare29). Parasites were detected in one preg-
nant woman at a revisit at day 49, classified as a new infection by 
genotyping. No recrudescent malaria was observed in any of the 
patients.
Demographic and clinical data are presented in Table 1. In both 
groups age, weight and height were comparable, but a higher 
parasite density and a significantly lower haemoglobin level were 
found in the pregnant women. The frequent sampling design 
resulted in full pharmacokinetic concentration-time profiles for 
artesunate and dihydroartemisinin in both groups. Artesunate was 
rapidly converted into dihydroartemisinin, and artesunate concen-
trations reached the LLOQ within six hours in all patients. 62% 
of the artesunate samples, and 21% of the dihydroartemisinin 
samples were measured to be below the LLOQ.
Pharmacokinetic analysis
The pharmacokinetic properties of artesunate and dihydroar-
temisinin were described simultaneously in a drug-metabolite 
model, assuming complete in vivo conversion of artesunate into 
dihydroartemisinin (Figure 1). A transit-compartment (n = 3) 
absorption model for artesunate was superior to all other absorp-
tion models tested (ΔOFV > 242). Allowing for inter-individual 
variability in the relative bioavailability of artesunate improved 
the model fit substantially (ΔOFV = 27). Artesunate disposition 
was defined by a central disposition compartment with no addi-
tional benefit of adding a peripheral disposition compartment 
(p > 0.05). Dihydroartemisinin was best described by a one-
compartment disposition model with first-order elimination. 
However, an additional peripheral disposition compartment 
for dihydroartemisinin improved the model fit significantly 
(ΔOFV = 21), but resulted in an unrealistic terminal elimination 
half-life of 9 hours and was therefore not carried forward30–33. 
Table 1. Admission demographics of study population.
Parameter Pregnant women 
median (range)
Non-pregnant women 
median (range)
Number of patients 24 24
Age (year) 20.5 (18–39) 25 (18–48)
Weight (kg) 52 (46–70) 53 (45–70)
Height (cm) 160 (150–170) 160 (160–170)
Parasite density (count/µL) 810 (79–54,000) 240 (18–2,444)
Haemoglobin (g/dL) 9.10 (7.1–11) 12 (7.8–14)
AST (units/L) 20 (3.2–84) 27.9 (8.2–59.8)
ALT (units/L) 20.3 (3.2–63) 21.75 (9.9–61.2)
Bilirubin (mg/dL) 0.45 (0.2–1.9) 0.5 (0.2–2)
Gestational age (month)
Second trimester, n=12 5 (4–5) 0
Third trimester, n=12 7 (6–8) 0
AST, aspartate aminotransferase; ALT, aspartate aminotransferase
Figure 1. Structural representation of the final population pharmacokinetic model. ARS is artesunate; DHA is dihydroartemisinin; 
kTR is the absorption rate constant; CL/F is the apparent elimination clearance; V/F is the apparent volume of distribution; F is the relative 
bioavailability of artesunate.
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Figure 2. Prediction-corrected visual predictive check of the final population pharmacokinetic model. Predictive performance of 
the final population pharmacokinetic model of artesunate (A) and dihydroartemisinin (B) in pregnant and non-pregnant women. 
Open circles (upper panel) represent the observed concentrations and the solid lines represent the 5th, 50th and 95th percentiles of the 
observed concentrations. Shaded areas show the 95% confidence interval of the 5th, 50th and 95th percentiles of simulated concentrations. 
Solid black lines (lower panel) represent the observed fraction of data below the lower limit of quantification and the shaded area represents 
the 95% confidence intervals of simulated data below the lower limit of quantification for artesunate (C) and dihydroartemisinin (D).
A third disposition compartment did not improve the model fit 
(p > 0.05). Ignoring data below the LLOQ (missing data) or 
imputing them as half the LLOQ resulted in model misspeci-
fications due to the large fraction of censored data (results not 
shown). The best performing model was obtained when data below 
the LLOQ was modelled as categorical data (i.e. M3), thereby 
maximizing the probability that observations below the LLOQ 
are predicted to be below the LLOQ (Figure 2). Inter-individual 
variability was retained on artesunate elimination clearance, 
dihydroartemisinin elimination clearance, mean–transit-time, 
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Figure 3. The impact of pregnancy on primary pharmacokinetic parameters. Box and whisker plot of the results from the full covariate 
model investigating pregnancy as a categorical covariate. Boxes represent the 25th to 75th percentiles and whiskers represent the 10th to 90th 
percentiles. The solid vertical line represents no covariate effect and the dashed vertical lines represent a covariate effect of ±20%, which 
is assumed to be associated with clinical significance. F is the relative oral bioavailability, CLARS/F is the apparent elimination clearance of 
artesunate, CLDHA/F is the apparent elimination clearance of dihydroartemisinin, and MTT is the mean absorption transit time. The covariate 
was added as a categorical function and bootstrapped (n=500).
and relative bioavailability. A separate additive error model for 
artesunate and dihydroartemisinin, respectively, described the 
random residual variability adequately.
Body weight implemented as an allometric function on clearance 
and volume parameters, improved the model fit (ΔOFV = 6.3) 
and was retained in the final model due to the strong biological 
prior of this covariate, and to remove the potential bias of 
systematically different body weights between pregnant and non- 
pregnant women. Pregnancy as a categorical covariate had a 
significant (ΔOFV = 19) impact on oral clearance of dihydroar-
temisinin, resulting in a 21% increased elimination clearance 
of dihydroartemisinin in pregnant women as compared to non- 
pregnant women. In addition, parasite biomass and ALT at enrol-
ment were found to be significant covariates on the relative 
bioavailability; 14% increase in relative bioavailability per each 
increase in the natural logarithm of the parasite biomass, and 2.2% 
increase in relative bioavailability per each increase in ALT).
The full covariate approach investigating the impact of preg-
nancy confirmed the above covariate relationship, resulting in 
an increased dihydroartemisinin elimination clearance of 24% 
in pregnant women, causing a proportional decrease in total 
drug exposure to dihydroartemisinin (Figure 3). Final parameter 
estimates are summarized in Table 2.
The final model showed satisfactory goodness-of-fit diagnos-
tics for both artesunate and dihydroartemisinin (Figure 4 and 
Figure 5) and predictive performance (Figure 2). The pharma-
cometric model code is available in Table 3. Calculated epsilon- 
shrinkage was low (11.1% and 10.4% for artesunate and 
dihydroartemisinin, respectively) indicating that model diagnos-
tics can be assessed reliably. However, the estimated eta shrinkage 
was relatively high for clearance parameters (i.e. artesunate clear-
ance = 30%, dihydroartemisinin clearance = 40%, mean tran-
sit time = 5.7%, bioavailability = 25%) and empirical Bayes 
estimates should therefore be interpreted with caution28. Simu-
lations of the exposure to artesunate and dihydroartemisinin 
in pregnant and non-pregnant women can be seen in Figure 6.
Discussion
In this study, a population pharmacokinetic model was devel-
oped for artesunate and dihydroartemisinin in pregnant and 
non-pregnant women in Burkina Faso, treated with a fixed-dose 
combination of artesunate and mefloquine. The final model was a 
one-compartment disposition model for both artesunate and its 
active metabolite, dihydroartemisinin. Artesunate absorption was 
described with a flexible transit compartment model allowing 
for inter-individual variability in the relative bioavailability. Preg-
nancy had a significant impact on the elimination clearance of 
dihydroartemisinin, resulting in a 21% reduced drug exposure 
compared to non-pregnant women.
Artesunate and dihydroartemisinin population pharmacokinet-
ics have been described previously with one-compartment dis-
position models in pregnant and non-pregnant women after oral 
administration, supporting the present findings12,31. The pregnancy- 
related alterations on the pharmacokinetic properties of the 
artemisinins derivatives are also supported in literature. Morris 
et al. found a pregnancy-induced increase of 42% in the elimina-
tion clearance of dihydroartemisinin12. In the study by Tarning 
et al.31, where oral dihydroartemisinin was administered alone, 
pregnancy was found to influence the bioavailability of dihy-
droartemisinin resulting in a 38% reduction in the exposure in 
pregnant compared to non-pregnant women. The present analy-
sis also identified parasite biomass as a covariate on the relative 
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Figure 4. Goodness-of-fit diagnostics of the final population pharmacokinetic model for artesunate. Descriptive performance of the 
final population pharmacokinetic model in pregnant and non-pregnant women. Lines represent weighted least-squares regression (dashed) 
and lines of identity (solid).
Table 2. Final model parameters describing artesunate and 
dihydroartemisinin population pharmacokinetics in pregnant and non-
pregnant women.
Parameters Population estimate (RSE%) CI. 95%
IIV CV% 
(RSE%) CI. 95%
F (%) 100 fixed - 30.5 (20.0) 16.8-38.7
Nr. of trans comp 3 fixed - - -
MTT (h) 0.832 (8.56) 0.695-0.979 61.4 (12.8) 46.2-76.0
CLARS/F (L/h) 3,570 (9.22) 2,990-4,290 26.4 (27.5) 5.47-35.2
VARS/F (L) 1,700 (11.2) 1,370-2,110 - -
CLDHA/F (L/h) 190 (5.87) 168-213 9.00 (23.7) 3.63-11.6
VDHA/F (L) 267 (6.49) 236-301 - -
PREGCL_DHA (%) 21.4 (16.3) 14.3-27.9 - -
ALTF (%) 2.15 (29.2) 1.10-3.57
BiomassF (%) 13.8 (23.6) 7.32-20.0
σARS 0.892 (11.5) 0.707-1.10 - -
σDHA 0.660 (9.84) 0.534-0.780 - -
ARS, artesunate; DHA, dihydroartemisinin; CL/F, apparent elimination clearance;  
V/F, apparent volume of distribution; MTT, mean transit time of the absorption phase; F, relative 
oral bioavailability; Nr. trans comp, number of transit compartments in the absorption model; 
PREGCL_DHA, proportional increase in CLDHA/F with pregnancy; ALTF, linear increase in F with 
ALT; BiomassF, linear increase in F with parasite biomass at enrolment; σ, additive residual 
error as variance. 
RSE is the relative standard error calculated as 100x standard deviation/mean. CV% is the 
coefficient of variation calculated as 100 ( 1)variancee× −  for inter-individual variability (IIV). Population 
parameter and IIV estimates are estimated directly by NONMEM. RSE% and 95% confidence 
intervals (CI. 95%) are based on 860 successful bootstrap runs (out of 1,000).
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Figure 5. Goodness-of-fit diagnostics of the final population pharmacokinetic model for dihydroartemisinin. Descriptive performance 
of the final population pharmacokinetic model in pregnant and non-pregnant women. Lines represent weighted least-squares regression 
(dashed) and lines of identity (solid).
bioavailability, resulting in an increased exposure to artesunate 
and dihydroartemisinin in patients with higher initial parasi-
taemia. This covariate effect has been identified also in another 
study14. This previously published clinical study showed 
opposite pharmacokinetic effects of malaria (87% increase) and 
pregnancy (23% decrease) on the absolute oral bioavailability 
of artesunate13,14. A sequential intravenous and oral dosing 
regimen in pregnant and post-partum women during the acute 
malaria phase and at recovery (i.e. healthy) enabled these covariate 
effects to be dissected and quantified. The results in the 
present study support these findings. In addition to the disease 
effect, liver status (ALT) was found to affect the relative 
bioavailability, resulting in an increased exposure with decreased 
liver status (i.e. increased ALT levels). This is likely to be 
explained by a decreased first-pass metabolism of artesunate.
The full covariate approach supported the step-wise covariate 
results, demonstrating a mean increased dihydroartemisinin clear-
ance of 24% in pregnant women compared to non-pregnant women. 
There was also a trend towards a decreased mean transit absorp-
tion time in pregnant women. This suggests that an additional 
pregnancy effect in the absorption phase might be significant 
in a larger patient study. There was also a trend of decreasing 
artesunate clearance in pregnant women but it could not be 
substantiated by the step-wise covariate results.
The non-compartmental analysis of this clinical study by Valea 
et al., demonstrated an increased exposure to artesunate in 
pregnant women, resulting from an unexplained decrease in 
artesunate elimination clearance22. This decrease was considered 
highly contradictive since elimination generally increases during 
pregnancy due to induced enzyme systems34. The increased artesu-
nate exposure could not be explained by a model-independent 
analysis. Also, no significant differences were found in the 
exposure to dihydroartemisinin in the model-independent 
analysis, but large variability was noted and thus limited power to 
detect differences. In the present paper, a model based approach 
was implemented for a more mechanistic understanding of the 
impact of pregnancy on the pharmacokinetics of artesunate 
and dihydroartemisinin. In contradiction to the NCA analysis, 
no pregnancy related effect was found on clearance for artesu-
nate although a trend towards a decreased clearance was seen 
in the full covariate model.
It is well known that haemoglobin levels are decreased in preg-
nant women due to the increased need of iron for the mother 
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Table 3. Final population pharmacokinetic model of artesunate and dihydroartemisinin in 
pregnant and non-pregnant women with uncomplicated falciparum malaria.
$INPUT 
          ID                           ; Patient ID 
          TIME                      ; Time of sample 
          DV                          ; Dependent variable (natural logarithm of observed concentrations) 
          WT                          ; Body weight (covariate) 
          EVID                       ; Event ID record 
          MDV                       ; Missing dependent variable (1=missing) 
          AMT                        ; Dose amount 
          CMT                        ; Compartment (1=dose, 2=artesunate, 3=dihydroartemisinin) 
          BQL                        ; Below quantification limit (1=below BQL) 
          PREG                      ; Pregnancy (covariate; 0=non-pregnant, 1=pregnant) 
          LNPC                      ; Parasite count (covariate; natural logarithm of parasite count) 
          HB                          ; Haemoglobin measurement (covariate) 
          AST                         ; AST (covariate) 
          ALT                         ; ALT (covariate) 
          BIL                          ; Bilirubin (covariate) 
          EGA                        ; Estimated gestational age (covariate) 
 
$DATA  
          dataset.csv IGNORE=# 
 
$SUBROUTINE  
          ADVAN5 TRANS1 
 
$MODEL  
          COMP = (1)            ; Dose 
          COMP = (2)            ; Artesunate 
          COMP = (3)            ; Dihydroartemisinin 
          COMP = (4)            ; Transit compartment 1 
          COMP = (5)            ; Transit compartment 2 
          COMP = (6)            ; Transit compartment 3 
 
$PK 
;--------------------------------Pregnancy covariate---------------------------------------------------------------------------- 
          PREGNANCY = (1 + THETA(7) * PREG)        ; Linear covariate relationship for pregnancy 
;---------------------------------------------------------------------------------------------------------------------------------------- 
 
;------------------------------Liver status covariate------------------------------------------------------------------------------ 
          LIVER = (1 + THETA(8) * (ALT - 20.75))         ; Linear covariate relationship for liver status 
;---------------------------------------------------------------------------------------------------------------------------------------- 
 
;------------------------------Parasite biomass covariate---------------------------------------------------------------------- 
          PARASITE = (1 + THETA(9) * (LNPC - 5.88)) ; Linear covariate relationship for parasite biomass 
;---------------------------------------------------------------------------------------------------------------------------------------- 
 
          TVCLP   = THETA(1) * ((WT/52)**0.75)                                     ; Population artesunate clearance 
          CLP       = TVCLP * EXP(ETA(1))                                               ; Individual artesunate clearance 
 
          TVV2     = THETA(2) * ((WT/52)**1)                                           ; Population artesunate volume 
          V2         = TVV2 * EXP(ETA(2))                                                  ; Individual artesunate volume 
 
          TVCLM  = THETA(3) * ((WT/52)**0.75) * PREGNANCY            ; Population DHA clearance 
          CLM      = TVCLM * EXP(ETA(3))                                              ; Individual DHA clearance 
 
          TVV3     = THETA(4) * ((WT/52)**1)                                           ; Population DHA volume 
          V3         = TVV3 * EXP(ETA(4))                                                  ; Individual DHA volume 
 
          TVMT    = THETA(5)                                                                  ; Population mean transit time 
          MT        = TVMT * EXP(ETA(5))                                                 ; Individual mean transit time 
 
          TVF1     = THETA(6) * LIVER * PARASITE                                 ; Population relative bioavailability 
          F1         = TVF1 * EXP(ETA(6))                                                  ; Individual relative bioavailability 
 
          NN        = 3                                  ; Number of transit compartments 
          KTR       = (NN + 1) / MT              ; Transit rate constant 
          K14       = KTR                            ; Transit rate between compartment 1 and 4
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          K45       = KTR                        ; Transit rate between compartment 4 and 5 
          K56       = KTR                        ; Transit rate between compartment 5 and 6 
          K62       = KTR                        ; Transit rate between compartment 6 and 2 
 
          K23       = CLP / V2                 ; Elimination of artesunate 
          K30       = CLM / V3                ; Elimination of dihydroartemisinin 
 
$ERROR 
          IF(CMT.EQ.2) THEN 
              IPRED = A(2) / V2               ; Predicted plasma concentration of artesunate 
              W = SQRT(SIGMA(1,1))      ; Residual error artesunate 
          ENDIF 
 
          IF(CMT.EQ.3) THEN 
              IPRED = A(3) / V3               ; Predicted plasma concentration of dihydroartemisinin 
              W = SQRT(SIGMA(2,2))      ; Residual error dihydroartemisinin 
          ENDIF 
 
          IF(IPRED.GT.0)  IPRED = LOG(IPRED)  ; Natural logarithm of predictions 
 
 
;-------------------------------M3-method for incorporating concentratoins below LLOQ---------------------------- 
          DUM = (LLOQ-IPRED) / W 
          CUMD = PHI(DUM) 
;--------------------------------------------------------------------------------------------------------------------------------------- 
 
; -----------------------------------------Prediction DV>=LLOQ------------------------------------------------------------- 
          IRES = IPRED - DV 
          IWRES = IRES / W 
          IF(BQL.EQ.0.AND.CMT.EQ.2) THEN      ; Calculating Y for artesunate 
              F_FLAG = 0 
              Y = IPRED + ERR(1) 
          ENDIF 
 
          IF(BQL.EQ.0.AND.CMT.EQ.3) THEN      ; Calculating Y for dihydroartemisinin 
              F_FLAG = 0 
              Y = IPRED + ERR(2) 
          ENDIF 
;------------------------------------------------------------------------------------------------------------------------------------- 
 
;--------------------------------------------- Likelihood DV<LLOQ----------------------------------------------------------- 
          IF(BQL.EQ.1) THEN                                ; Calculating Y for data below LLOQ 
              F_FLAG = 1 
              Y = CUMD + 0.000001 
          ENDIF 
;------------------------------------------------------------------------------------------------------------------------------------- 
 
$THETA                                                             ; Initial estimates of theta 
           (0, 3570)                                                 ; 1. Artesunate clearance 
           (0, 1700)                                                 ; 2. Artesunate volume of distribution 
           (0, 190)                                                  ; 3. Dihydroartemisinin clearance  
           (0, 267)                                                   ; 4. Dihydroartemisinin volume of distribution 
           (0, 0.832)                                                ; 5. Mean transit time 
           (1 FIX)                                                     ; 6. Relative bioavailability 
           (-1, 0.214)                                               ; 7. Pregnancy effect on dihydroartemisinin clearance 
           (-0.024, 0.0215, 0.057)                           ; 8. Liver status effect on relative bioavailability 
           (-0.199, 0.138, 0.334)                             ; 9. Parasite biomass effect on relative bioavailability 
 
$OMEGA                                                           ; Initial estimates for omega 
          (0.0672)                                                   ; 1. IIV artesunate clearance 
          (0 FIX)                                                      ; 2. IIV artesunate volume of distribution 
          (0.00810)                                                 ; 3. IIV dihydroartemisinin clearance 
          (0 FIX)                                                      ; 4. IIV dihydroartemisinin volume of distribution 
          (0.320)                                                     ; 5. IIV mean transit time 
          (0.0887)                                                   ; 6. IIV relative bioavailability 
 
$SIGMA                                                             ; Initial estimates of sigma 
          (0.892)                                                     ; Residual variability artesunate 
          (0.660)                                                     ; Residual variability dihydroartemisinin
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Figure 6. The impact of pregnancy on secondary pharmacokinetic parameters. Relative effect of pregnancy on simulated exposure (AUC 
and CMAX) to artesunate and dihydroartemisinin. The final model was used to simulate 1,000 non-pregnant and pregnant woman after an oral 
single dose of artesunate. All individual exposure parameters were divided on the average value for a non-pregnant women, to generate 
relative pregnancy effects. Boxes represent the 25th to 75th percentiles and whiskers represent the 10th to 90th percentiles. The vertical black 
line represents no covariate effect and the dashed vertical lines represent a covariate effect of ±20%, which is assumed to be associated 
with clinical significance.
and the foetus35. Indeed, haemoglobin levels were significantly 
lower in the pregnant group in this study. However, haemoglobin 
was not a significant covariate in the present study when preg-
nant and non-pregnant women were modelled simultaneously and 
separately.
In conclusion, a population pharmacokinetic model was devel-
oped for artesunate and dihydroartemisinin. A pregnancy 
related increase in the elimination of dihydroartemisinin was 
found, resulting in a proportionally decreased exposure to 
dihydroartemisinin. This could result in an increased risk of 
failure and possibly a need of increased dosing of artesunate dur-
ing pregnancy; especially in low-transmission settings where 
the acquired immunity is relatively lower. However, the clini-
cal relevance of a lower exposure needs to be further evaluated in 
prospective studies.
Data availability
Underlying data
Due to ethical and security considerations, the data that 
supports the findings in this study can be accessed only through 
the Data Access Committee at Mahidol Oxford Tropical 
Medicine Research Unit (MORU). The application form and data 
sharing policy can be found here: http://www.tropmedres.ac/data-
sharing.
The full NONMEM model code describing the final population 
pharmacokinetic model is available in Table 3, and also in the 
open pharmacometric model repository hosted by DDMoRe.
NONMEM model code, Accession number DDMODEL00000297: 
http://repository.ddmore.foundation/model/DDMODEL00000297/
Reporting guidelines
CONSORT checklist and flow diagram for “Population phar-
macokinetics of artesunate and dihydroartemisinin in pregnant 
and non-pregnant women with uncomplicated Plasmodium 
falciparum malaria in Burkina Faso” https://doi.org/10.6084/
m9.figshare.7699835.v129.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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Consent
The study was approved by the National Health Ethics 
Committee in Burkina Faso (014-2008/CE-CM). The study was 
registered at www.clinicaltrials.gov  (NCT00701961). Study 
procedures and objectives were explained in the local language by 
the study physician before obtaining a signed informed consent.
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